UNSPSC 51332868: Pipotiazine palmitate

This classification denotes a dopamine antagonist with the molecular formula C40H63N3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4Q3H01QRMI, chemically known as 10-(3-(4-(2-hydroxyethyl)piperidino)propyl)-n,n-dimethylphenothiazine-2-sulfonamide palmitate (ester) but more generally known as pipotiazine palmitate, which bears US NIH Compound Identifier 37767. European Medicines Agency schedules Pipotiazine palmitate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03860MIG.

UNSPSC 51332868 Pipotiazine palmitate is a Commodity code that, based on recent state and local procurement activity, does not map cleanly to actual solicitations under the code. The three recent opportunities posted across Florida, Texas, and Minnesota—covering naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products—represent broader pharmaceutical and medical supply procurement rather than pipotiazine palmitate specifically. The source shows no direct demand for pipotiazine palmitate, an antipsychotic injection, in recent state or local competitive solicitations.

The geographic spread of pharmaceutical and related health-services procurement appears concentrated in large state health agencies and cooperative purchasing alliances rather than uniform across jurisdictions. The Texas Health and Human Services Commission is exploring direct-to-manufacturer prescription models through an RFI, the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP)—administered by the Minnesota Department of Administration—issued an RFP for generic pharmaceuticals and OTC products serving participating states including Oregon, and Seminole County, Florida procured naloxone and drug deactivation systems through an IFB. The mismatch between the pipotiazine palmitate code and the pharmaceutical procurement activity actually visible in the market suggests either that the code carries minimal recent state and local volume or that jurisdictions tag broader pharmaceutical buys with higher-level family or class codes rather than this specific commodity designation.